News

Argenx Secures EC Approval for Subcutaneous VYVGART in CIDP Treatment
Argenx (NASDAQ:ARGX) is one of the best biotech stocks to invest in now. On June 20, Argenx announced that the European ...
Can monoclonal antibodies effectively treat malaria? Scientists say the answer is a resounding 'yes'
Monoclonal antibodies provide protection against a wide range of infectious microbes, and now, in a series of elegant ...
PipelineReview.com15h
Cidara Therapeutics Announces Positive Topline Results from its Phase 2b NAVIGATE Trial Evaluating CD388, a Non-Vaccine Preventative of Seasonal Influenza
Single doses of 450mg, 300mg and 150mg of CD388 conferred 76%, 61% and 58% protection, respectively, from symptomatic influenza over 24 weeks compared to placebo End of Phase 2 meeting request has ...
C&EN1d
Engineered Recombinant Single-Chain Fragment Variable Antibody for Immunosensors
Department of Chemistry, Oakland University, Rochester, Michigan 48309, and Department of Biochemistry, School of Medicine, Vanderbilt University, Nashville, Tennessee 37232 Article Views are the ...